Pulmonology

EGFR+

Questions discussed in this category

Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?

Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?

1 Answer available

Papers discussed in this category

J. Clin. Oncol., 2008-07-20

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol, 2021 Nov 02

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT).

Related Topics in Pulmonology